Variabilidad farmacocinética de oxcarbazepina en pacientes epilépticos / Pharmacokinetic variability of oxcarbazepine in epileptic patients
Medicina (B.Aires)
; 60(6): 914-918, 2000. tab, graf
Article
em Es
| LILACS
| ID: lil-305299
Biblioteca responsável:
BR1.1
ABSTRACT
The aim of this study was to analyze the population pharmacokinetics of oxcarbazepine (OCBZ) measuring the serum level of its active metabolite, monohydroxylated oxcarbazepine (MHD). We studied a group of patients with symptomatic and cryptogenic epilepsy treated with OCBZ monotherapy orally, at least for 3 weeks. The mean doses, age and weight of the patients were 17.9 +/- 7.8 mg/kg/day, 35.6 +/- 16.4 years and 70.3 +/- 19.2 kg, respectively. Blood samples were taken before the first morning dose of OCBZ and MHD levels were determined by HPLC. A linear relationship was found between OCBZ dose and MHD serum level (r = 0.844, p < 0.001). The MHD serum concentration (mg/l) can be predicted as 0.85 x OCBZ dose (mg/kg). There was a significant correlation between observed and predicted MHD concentrations for each patient. The mean MHD clearance (Cl/F) calculated was 4.05 +/- 1.69 l/h, with a coefficient variation of 41%. It was independent of dose, age and weight and followed a non normal distribution. The half-life of MHD was 10.50 +/- 3.17 hours. The influence of other antiepileptic drugs on MHD pharmacokinetics was analyzed by comparing the Cl/F medians from groups of patients receiving concomitant drugs with OCBZ monotherapy group where no significant differences were found. The results can be used to estimate a priori OCBZ doses, in order to individualize the treatment.
Buscar no Google
Coleções:
01-internacional
Base de dados:
LILACS
Assunto principal:
Carbamazepina
/
Epilepsia
/
Anticonvulsivantes
Limite:
Adolescent
/
Adult
/
Aged80
/
Child
/
Female
/
Humans
/
Male
Idioma:
Es
Revista:
Medicina (B.Aires)
Assunto da revista:
MEDICINA
Ano de publicação:
2000
Tipo de documento:
Article
País de afiliação:
Argentina